Trevi Therapeutics launches $150M public stock offering [Seeking Alpha]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Seeking Alpha
The company also plans to grant underwriters a 30-day option to purchase up to an additional $22.5M in shares. Proceeds will support development of Haduvio (oral nalbuphine ER), its investigational therapy for chronic cough conditions. Fresh Stock Ideas, Every Day More on Trevi Therapeutics Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved Trevi Therapeutics GAAP EPS of -$0.06 beats by $0.04 Seeking Alpha's Quant Rating on Trevi Therapeutics
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics: Late-Stage Transition Meets Execution Risk [Seeking Alpha]Seeking Alpha
- Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.MarketBeat
- Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common StockGlobeNewswire
- Trevi Therapeutics Announces Proposed Public Offering of Common StockGlobeNewswire
- A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 3/17/26 - Beat
TRVI
Sec Filings
- 4/17/26 - Form 424B5
- 4/17/26 - Form 8-K
- 4/16/26 - Form 424B5
- TRVI's page on the SEC website